YMAB News and Press, Y-mAbs Therapeutics Inc. From 11/02/22

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....

Wedbush has downgraded Y-mAbs Therapeutics ( NASDAQ: YMAB ) to neutral following a US FDA panel's unanimously decision Friday to reject omburtamab for pediatric neuroblastoma. The firm cut its price target to $6 from $21 (~33% downside based on Friday's close). Ana...

Summary Shares have lost 45% in 2022 and are down by 58% since my 2019 article. Conservative peak sales estimate of $200M for Danyelza contrasts favorably to current enterprise value of $260M. SADA technology intends to greatly increase therapeutic index of  radiopharmace...

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...

An expert panel of the FDA unanimously voted against approving the marketing application submitted by Y-mAbs Therapeutics, Inc. ( NASDAQ: YMAB ) for omburtamab, an experimental therapy for rare cancer neuroblastoma. On the question of "Has Applicant provided sufficient evi...

New York, New York--(Newsfile Corp. - October 27, 2022) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") common stock (NASDAQ: YMAB). Y-mAbs is developing omburtamab, which is used to treat ch...

Despite US FDA briefing documents released Wednesday expressing concerns about efficacy for Y-mAbs Therapeutics' ( NASDAQ: YMAB ) omburtamab for neuroblastoma, Citi is confident the candidiate can win approval. Shares are down 19% in Thursday afternoon tr...

BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn more about how t...

US FDA scientists are concerned that data submitted in support of Y-mAbs' Therapuetics ( NASDAQ: YMAB ) Biologics License Application for its neuroblastoma therapy omburtamab does not provide substantial evidence of efficacy. In briefing documents posted Wednesday in adv...

NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the t...